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Background: Argininosuccinate synthetase (ASS) participates in urea and nitric oxide production and is a rate-
limiting enzyme in arginine biosynthesis. Regulation of ASS expression appears complex and dynamic. In addition
to transcriptional regulation, a novel post-transcriptional regulation affecting nuclear precursor RNA stability has
been reported. Moreover, many cancers, including hepatocellular carcinoma (HCC), have been found not to express
ASS mRNA; therefore, they are auxotrophic for arginine. To study when and where ASS is expressed and whether
post-transcriptional regulation is undermined in particular temporal and spatial expression and in pathological
events such as HCC, we set up a transgenic mouse system with modified BAC (bacterial artificial chromosome)
carrying the human ASS gene tagged with an EGFP reporter.
Results: We established and characterized the transgenic mouse models based on the use of two BAC-based EGFP
reporter cassettes: a transcription reporter and a transcription/post-transcription coupled reporter. Using such a
transgenic mouse system, EGFP fluorescence pattern in E14.5 embryo was examined. Profiles of fluorescence and
that of Ass RNA in in situ hybridization were found to be in good agreement in general, yet our system has the
advantages of sensitivity and direct fluorescence visualization. By comparing expression patterns between mice
carrying the transcription reporter and those carrying the transcription/post-transcription couple reporter, a post-
transcriptional up-regulation of ASS was found around the ventricular zone/subventricular zone of E14.5 embryonic
brain. In the EGFP fluorescence pattern and mRNA level in adult tissues, tissue-specific regulation was found to be
mainly controlled at transcriptional initiation. Furthermore, strong EGFP expression was found in brain regions of
olfactory bulb, septum, habenular nucleus and choroid plexus of the young transgenic mice. On the other hand, in
crossing to hepatitis B virus X protein (HBx)-transgenic mice, the Tg (ASS-EGFP, HBx) double transgenic mice
developed HCC in which ASS expression was down-regulated, as in clinical samples.
Conclusions: The BAC transgenic mouse model described is a valuable tool for studying ASS gene expression.
Moreover, this mouse model is a close reproduction of clinical behavior of ASS in HCC and is useful in testing
arginine-depleting agents and for studies of the role of ASS in tumorigenesis.
Keywords: Argininosuccinate synthetase, Transgenic mouse model, Hepatocellular carcinoma, Embryo expression
map, Brain expression map, Ventricular zone, Subventricular zone, Post-transcriptional regulation, Bacterial artificial
chromosome, GFP reporter gene* Correspondence: su31659@gmail.com
1Institute of Microbiology & Immunology, National Yang-Ming University,
Taipei, Taiwan
2Department of Medical Research, Taipei Veterans General Hospital, Taipei
112, Taiwan
Full list of author information is available at the end of the article
© 2015 Shiue et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Shiue et al. Journal of Biomedical Science  (2015) 22:10 Page 2 of 14Background
Argininosuccinate synthetase (ASS; EC 6.3.4.5) catalyzes
the conversion of citrulline and aspartate to argininosuc-
cinate, which is subsequently converted to arginine by
argininosuccinate lyase. Arginine plays an important role
in the synthesis of urea, nitric oxide (NO) and polyamines,
among other metabolites [1]. In the process, ASS fine-
tunes NO production to maintain cellular homeostasis
in response to cellular and environmental stimuli. ASS
is ubiquitously expressed but the highest enzyme activ-
ities are found in the urea cycle in the liver to eliminate
ammonia [2,3].
Regulation of ASS expression is complex and dynamic.
Hormones, including glucocorticoid, glucagon and insu-
lin, are major regulators of the expression of urea cycle
enzymes, including ASS, in the liver [2]. We have re-
ported an upstream cAMP response element (CRE) tar-
geted by the CRE-binding protein (CREB) to mediate
glucagon action [4]. On the other hand, ASS expression
in non-hepatic cells has been shown to be induced by
interleukin-1β through NF-κB activation via a putative
NF-κB binding site in the ASS promoter [5]. ASS gene
expression also involves interactions between positive
transcriptional factors c-Myc and Sp4 and negative fac-
tor HIF-1α in the proximal promoter [6]. Furthermore,
we have described a novel post-transcriptional event in a
canavanine-resistant variant of a human epithelial cell
line that regulates the stability of ASS nuclear precursor
RNA, resulting in elevated ASS activities [7,8]. In addi-
tion, our recent study showed that the formation of the
3′-end of the human ASS mRNA is modulated by a highly
polymorphic GT microsatellite located downstream of the
poly (A) signal [9]. The identified post-transcriptional
regulation events may have physiological relevance and is
an added mechanism for tight regulation of ASS expres-
sion. Of clinical significance is the finding that ASS tran-
scription is stimulated by glutamine and repressed by
arginine in mammalian tissue cultures [10–12].
A number of tumor types, including hepatocellular
carcinoma (HCC), melanoma, prostate, pancreatic and
renal cancers, clearly show down-regulated ASS expres-
sion and are auxotrophic to arginine [13–15]. In HCC,
down-regulated ASS expression has been linked to clini-
copathological features and post-resectional patient sur-
vival [16,17]. Loss of ASS expression has been exploited
as a predictive biomarker for cancers including ma-
lignant pleural mesothelioma and epithelial ovarian tu-
mor, to name a few [18,19]. Clinical applications of an
arginine-depleting enzyme, such as arginine deaminase
(ADI), to treat ASS-deficient tumors have been tested,
opening up new venues for further development of
auxotrophic cancer therapy [15].
To investigate transcriptional and post-transcriptional
regulation of the ASS gene, we established a transgenicmouse system using a modified bacterial artificial chro-
mosome (BAC) carrying the human ASS gene tagged
with the enhanced green fluorescent protein (EGFP) re-
porter gene [20]. Two transgenic mouse lines were gener-
ated. One line was Tg (ASS-Ex3-EGFP) which carries the
transcription reporter BAC (ASS-Ex3-EGFP) (Figure 1A),
where EGFP was knocked-in at the initiation codon of the
human ASS gene and EGFP transcription is terminated by
a SV40 poly (A) signal. EGFP activities of Tg (ASS-Ex3-
EGFP) mainly reflect promoter activities of the ASS
gene. Another line Tg (ASS-Ex16-EGFP) carries the tran-
scription/post-transcription couple reporter BAC (ASS-
Ex16-EGFP) (Figure 1A), where EGFP with an internal
ribosome entry site (IRES) is inserted into the terminal
exon at site between the stop codon and the polyA signal
of the ASS gene; in such a configuration, translation of
EGFP in the bicistronic transcript is regulated by the IRES
mechanism. EGFP activities thus expressed are subjected
to both transcriptional and post-transcriptional regula-
tion as that of the endogenous ASS mRNA. Using these
transgenic mouse lines, we have taken liver, the organ
for urea production, intestine and kidney that are re-
sponsible for arginine biosynthesis as a model for tem-
poral and spatial expression analyses [20]. We found
the expression of the EGFP reporter gene in the trans-
genic mice faithfully reproduced that of the endogenous
gene, suggesting that sufficient ASS regulatory elements
are included in the transgene. Moreover, compari-
son between the EGFP expression profiles of the two
transgenic lines indicated the developmental and tissue-
specific regulation is mainly controlled at the transcrip-
tional level [20].
To demonstrate the merit of this transgenic mouse
system in studying ASS gene expression, we further
characterized the copy numbers and integration pat-
terns of transgenes. We then examined the EGFP ex-
pression pattern in the embryo and in adult tissues,
including the brain. Furthermore, to mimic clinical fea-
tures of affected ASS gene expression in tumor tissues,
the BAC (ASS-EGFP) transgenic mice were crossed to
transgenic mice carrying the HBx gene of hepatitis B
virus to induce HCC.
Methods
Animals
The mice were maintained in specific pathogen-free
area of the animal holding facilities and were treated
according to protocols approved by the Animal Care
and Use Committee of the Taipei Veterans General Hos-
pital. The transgenic mouse lines Tg (ASS-Ex3-EGFP) Tsu
and Tg (ASS-Ex16-EGFP) Tsu have been deposited in
the Rodent Model Resource Center, National Laboratory
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Figure 1 Analysis of the transgene structure in the BAC (ASS-EGFP) transgenic mice. (A) Overall view of BAC (ASS-EGFP) constructs
showing relative positions of the EGFP transgene and the human ASS exons. Insertions of the EGFP gene with a polyadenylation signal into exon
3 (EGFP-pA) or an IRES-EGFP sequence into exon 16 of the ASS gene of BAC clone RP11-52B13 created the BAC (ASS-Ex3-EGFP) and BAC
(ASS-Ex16-EGFP) constructs, respectively. The lengths of the 5′ and 3′ human genomic sequences included in the BAC construct and the ASS
structural gene are shown. Wavy line at the end represents the vector sequence. (B) Determination of transgene copy number. Genomic DNAs
from offspring of the second generation transgenic mice (F2) was digested with EcoRI and Southern blot analysis was performed using an EGFP
probe. The horizontal grey arrows are schematic representation of the transgene; the green bars represent the EGFP sequence; downward arrows
indicate the EcoRI sites shown with expected sizes of the hybridized EcoRI fragments. The signal of a BAC (ASS-Ex3-EGFP) DNA preparation with
predetermined copy number was used to estimate the transgene copy number in the mouse lines. The abbreviated transgenic line designations
3G, 3 J and 16E, 16H were two different lines each from the BAC (ASS-Ex3-EGFP) and BAC (ASS-Ex16-EGFP) transgenes, respectively; the
abbreviated designations are also used in other figures. (C) Confirmation of head-to-tail transgene integration. The PstI sites (downward arrows)
and the expected 1,044-bp head-to-tail hybridized fragments are shown. The size of junction fragment may be greater than 939 bp (>939 bp)
which is determined by position of the next PstI site in the mouse genome. (D) Monitoring of ASS-EGFP transgene transmission by fluorescence
signals of tail samples. Pedigree analysis of the transgenic line Tg (ASS-Ex16-EGFP) 16 F is shown. Upper and lower rows were observed by
dissecting microscopy under fluorescent light or white light, respectively.
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of Tg (ASS-EGFP) transgenic mice
The human BAC clone, RP11-52B13, carrying ~170 kb of
the human genome including the entire human ASS struc-
tural gene of ~57 kb and its 5′ and 3′ flanking sequencesof 97 kb and 16 kb, respectively, was obtained from
Genome Center, National Yang-Ming University, Taiwan.
To construct the BAC transgene reporters, an in vivo
recombination technique developed by Gust et al. [21]
was used.
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used in pronucleus microinjection of FVB/N fertilized
eggs (Level Biotechnology Inc., Taiwan). Transgenic mice
were identified by PCR detection of the EGFP sequence
in tail DNA. The PCR forward primer, 5′-CGACCACT
ACCAGCAGAACAC-3′, was used for both lines while
the reverse primers, 5′-GAGCAGACAGGCTGACAACC-
3′ and 5′-AGGATGCTGGCTAGGATCG-3′, were for
Tg (ASS-Ex3-EGFP) and Tg (ASS-Ex16-EGFP), respect-
ively. All founders were bred independently with wild-
type FVB/N mice to obtain progenies.
Generation of Tg (ASS-Ex3-EGFP, HBx) and Tg (ASS-Ex16-
EGFP, HBx) double transgenic mice
A male transgenic mouse of the C57BL/6 strain carrying
the hepatitis B virus X protein (HBx) transgene, i.e., Tg
(HBxA0106) [22], was mated with female transgenic
mice of the FVB/N strain of Tg (ASS-Ex3-EGFP) or Tg
(ASS-Ex16-EGFP) to obtain double transgenic lines of Tg
(ASS-Ex3-EGFP, HBx) and Tg (ASS-Ex16-EGFP, HBx).
Progenies carrying the HBx transgene were identified by
PCR analysis of the presence of transgene sequence in
tail DNA using primers 5′-CCTCCTTGGGCAACC
TGTTCAG-3′ and 5′-ATGTGGCACTGAGGGACAT
GGC-3′. EGFP progenies were identified by PCR or by
visualization of tail fluorescence of two week-old litter-
mates under a fluorescence dissecting microscope.
Southern blot analysis
DNA from mouse tails was purified using standard
method. Tail DNA was digested with EcoRI or PstI and
subjected to Southern blot analysis using random primed-
labeled EGFP probe or other probes as indicated in the
text, and analyzed by autoradiography.
Northern blot analysis
To isolate total RNA, tissues were grinded to powder in
liquid nitrogen. The frozen powder was transferred to
TRIzol reagent (Invitrogen, Carlsbad, CA) in a MagNA
Lyser tube (Roche Applied Science, Indianapolis, IN)
and was homogenized. Supernatant was obtained for
RNA isolation following manufacturer’s instructions. For
northern blot analysis, RNA was denatured in glyoxal
before electrophoresis on a 1.2% agarose gel. RNA was
transferred to Hybond N+ nylon membrane (GE Health-
care Life Sciences, UK), hybridized to an EGFP or an
ASS cDNA probe and analyzed by a phosphorimager
(Molecular Dynamics, Sunnyvale, CA).
Gross anatomy and histochemical analysis
Mouse gross anatomy was performed following standard
protocols. In brief, mouse was sacrificed by suffocation
in a dry ice chamber. Images of internal organs after
peritoneal wall incision or after gastrointestinal tractremoval were acquired with a Canon PowerShot G11
digital camera built with blue filter (Sky-blue V/475 nm,
Biotransman Ltd., Taiwan). For frozen sections, tissues
collected were immersion in 4% buffered paraformalde-
hyde. After cryoprotected in graded sucrose solution, tis-
sues were embedded in OCT compound (Tissue Tec,
Sakara, Torrance, CA). Serial sections were collected from
Leica cryostat (Leica Biosystems, Wetzlar, Germany) and
mounted onto slides to examine EGFP expression by a
fluorescence microscope (Olympus DP72, Japan), a con-
focal microscope (Nikon AIR Confocal System, Japan) or
a digital slide scanner (Pannoramic Scan, 3DHISTECH
Ltd., Hungary). Slides were counterstained with DAPI
(4′,6-diamidino-2-phenylindole) (Roche Applied Science,
Indianapolis, IN). For histochemical studies, tissues fixed
in buffered paraformaldehyde and embedded in paraffin
were deparaffinized, hydrated in graded ethanol and
stained with hematoxylin and eosin (HE stain). For im-
munohistochemical studies, the tissue slides were first
deparaffinized and antigen retrieved. After blocking, the
slides were incubated overnight at 4°C with an anti-GFP
rabbit polyclonal antibody (Chemicon) or with a mouse
anti-ASS monoclonal antibody (BD Biosciences) both at
1:100 dilution. Subsequently, the slides were incubated
with a biotinylated secondary antibody and streptavidin
conjugated-HRP (horseradish peroxidase). The HRP was
visualized by the application of substrate chromogen DAB
(diaminobenzidine) (Dako, Glostrup, Denmark) to gener-
ate brown coloration where the slides were counterstained
with hematoxylin [20].
Results and discussion
Generation and characterization of BAC (ASS-EGFP)
transgenic mice
BAC (ASS-EGFP) transgenic mice were generated by
pronuclear microinjection of FVB/N fertilized eggs with
linearized transgene DNA. Mice harboring the transgene
sequences were initially screened by PCR detection of
the EGFP sequence in the genomic DNA of mouse
tails. Among the 41 litters produced from two injec-
tions of BAC (ASS-Ex3-EGFP) (Figure 1A), 14 were
EGFP-positive, and the mice are designated as Tg (ASS-
Ex3-EGFP). Among the 39 litters produced from a sin-
gle injection of BAC (ASS-Ex16-EGFP) (Figure 1A), 10
were EGFP-positive, and the mice are designated as Tg
(ASS-Ex16-EGFP). Fourteen Tg (ASS-Ex3-EGFP) foun-
ders and 10 Tg (ASS-Ex16-EGFP) founders were inde-
pendently bred with wild-type FVB/N mice. Transgenic
mosaic mice and mice carrying multiple integration loci
were not further studied here. On the other hand, mice
carrying multiple transgene copies at a single integration
site may have the advantages in providing better signal-to-
noise fluorescence signals in immunochemical analyses
of tissue sections [23]. Nevertheless, high transgene copy
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ing cellular trans-factors required for endogenous gene
expression. Accordingly, transgenic mice harboring both
high and low copy numbers were identified for subsequent
investigation.
The transgene copy number and integration pattern
were characterized by Southern blot analysis (Figure 1).
Results showed that the two Tg (ASS-Ex3-EGFP) lines
designated as Tg (ASS-Ex3-EGFP) 3G and Tg (ASS-Ex3-
EGFP) 3 J, abbreviated as 3G and 3 J in Figure 1 and in
subsequent figures, harbored ~30 and 2 copies of the
transgene, and the two Tg (ASS-Ex16-EGFP) lines, Tg
(ASS-Ex16-EGFP) 16E and Tg (ASS-Ex16-EGFP) 16H,
16E and 16H in the figures, harbored ~10 and 2 trans-
gene copies, respectively (Figure 1B). In addition, Tg
(ASS-Ex16-EGFP) 16 F, abbreviated as 16 F and carries 5
transgene copies (data not shown), was also used in sub-
sequent studies. In the analysis of the transgene integra-
tion, transgenic lines with high or low copy number all
showed the anticipated 1,044-bp junctional PstI fragment
of single head-to-tail integrations (Figure 1C). Minor
spurious bands were noted in line 3G that could be due to
minor rearrangements in the integrated transgenes, or oc-
currence of complex but minor transgene configurations.
The transgene copy number and the configuration were
stably transmitted in many generations of breeding (data
not shown). Interestingly, EGFP transgene transmission
was conveniently identified by direct visualization of fluo-
rescence in the tails of littermates under a fluorescence
dissecting microscope (Figure 1D), circumventing the te-
dious PCR-based identification of transgenic littermates.
ASS-EGFP transgene expression in the embryo
When transgenic mouse embryos at embryonic day 11.5
(E11.5) was examined under a fluorescence dissecting
microscope, particular structures that were presumably
expressing ASS became visible (Figure 2A). For example,
structures such as the brain and spinal cord show strong
signals in both 3 J and 16H lines. In this respect, others
have reported that mouse Ass mRNA is detectable as
early as E1.0-E3.5 [24,25]. Conceivably, ASS-EGFP trans-
genic mouse is an ideal system to trace spatial and tem-
poral ASS expression during embryonic development.
At E11.5, the EGFP expression pattern in the 3G line
was similar to those of 3 J and 16H (data not shown).
The 3G line, containing 30 transgene copies, is useful to
reveal structures with weaker levels of expression. More-
over, there was no apparent sequestration of transcrip-
tion factors to affect endogenous Ass gene expression
using this line in our study of developmental regulation
of liver, kidney and intestine [20]. Thus, 3G line was
chosen to further analyze ASS-EGFP expression in the
embryo. Serial frozen sagittal sections of E14.5 embryos of
the 3G line were prepared and a representative section isshown in Figure 2B. Of note, autofluorescence of wild-
type embryo was negligible when compared to EGFP
signals in the 3G line (data not shown). Strong EGFP
fluorescence was observed in structures including the ol-
factory epithelium, septum, midbrain, cranial ganglia,
spinal cord, dorsal root ganglia, liver and the midgut. The
pattern of ASS expression was similar to that of E14.5 em-
bryos studied by RNA in situ hybridization [28]. However,
the signal intensity of Ass RNA in situ is in general weak;
tissues with low expression may become undetectable.
Our transgenic mouse lines, thus, provide a sound model
system to study ASS-EGFP expression in vivo.
To address the issue whether post-transcriptional
regulation in ASS gene is in operation during embryonic
development, EGFP expression patterns in E14.5 em-
bryos of the Tg (ASS-Ex16-EGFP) line carrying the tran-
scription/post-transcription couple reporter were studied.
We found that the expression profiles were similar, yet
significantly higher levels of EGFP expression were de-
tected around the ventricular zone/subventricular zone
(VZ/SVZ) of the brain in the Tg (ASS-Ex16-EGFP) line,
i.e., 16E and 16 F, compared to that in the Tg (ASS-Ex3-
EGFP) line, i.e., 3G and 3 J (Figure 3). The embryonic
VZ/SVZ is the major site of neurogenesis of the mam-
malian telencephalon [29]. Our data suggest that there
is post-transcriptional up-regulation of ASS in cells
around VZ/SVZ. The mechanism and functional conse-
quences of such a mode of regulation need to be fur-
ther investigated.
Expression of the ASS-EGFP transgene in adult organs
ASS protein is ubiquitously expressed, albeit with signifi-
cant variations in the expression levels among tissues
and organs [2]. We have previously studied EGFP ex-
pression patterns in the liver, kidney and intestine in
both the Tg (ASS-Ex3-EGFP) and Tg (ASS-Ex16-EGFP)
lines and found that EGFP signals faithfully reproduced
the spatial and temporal expression patterns of the ASS
gene [20].
To further investigate the global ASS-EGFP expression
pattern in the transgenic mice, the gross anatomy of
adult Tg (ASS-Ex3-EGFP) 3G, i.e. 3G, was studied where
the salivary gland, liver, intestine, testis, pancreas and
the kidney were found to have strong EGFP fluorescence
signals (Figure 4A). When comparing the fluorescence
signals among the mouse lines, it is clear that high trans-
gene copy number in the 3G line, indeed, provided an
advantage to yield sufficient signal-to-noise fluorescence
ratio. It is noted that the 16E line, despite harboring 10
transgene copies (Figure 1B), showed considerably weak
EGFP fluorescence (Figure 4A). In the 16E line, the EGFP
gene is located at downstream of the bicistronic mRNA
that might affect the strength of IRES-dependent trans-
lation [30]. Organs of interest were examined (Figure 4B).
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Figure 2 ASS-EGFP reporter gene expression in the embryo of the transgenic mice. (A) Embryos of Tg (ASS-Ex3-EGFP) 3 J and Tg
(ASS-Ex16-EGFP) 16H mice at E11.5 were examined under a fluorescence dissecting microscope. Images on the left and right were observed under
white or fluorescent light, respectively. (B) Annotated expression pattern of E14.5 embryo of Tg (ASS-Ex3-EGFP) 3G. Serial frozen sagittal sections
were collected and a representative section is shown. The sectional plane (red line) relative to the intact embryo is inserted in the bottom right
corner where the embryo marking is adapted from GenePaint.org [26]. The structures are labelled based on Kaufman [27] and GenePaint.org [26].
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located in the anterior part of the brain showed strong
EGFP signals (Figure 4B, (a)). Mapping the expression pat-
tern of ASS in the brain is a key to understanding its func-
tional significance in the nervous system. We, therefore,
studied ASS-EGFP expression in the brain as presented inFigure 5. On the other hand, the pancreas showed strong
EGFP fluorescence signals in contrast to no signals in
the spleen when examined macroscopically (Figure 4A
and B, (b) (ii)). However, in frozen sections, spleen
did show some signals (Figure 4B, (b) (iii)), while sig-



























Figure 3 Post-transcriptional up-regulation of ASS in cells around the ventricular zone/subventricular zone (VZ/SVZ) in E14.5 embryo
of the Tg (ASS-Ex16-EGFP) line. (A) A frozen sagittal image of E14.5 embryo from the 16E line is shown. The sectional plane (red line) relative to
the intact embryo is inserted in the bottom left corner where the embryo marking is adapted from GenePaint.org. [26] (B) Comparable region
(boxed field in A) from each mouse line was selected and magnified. Red arrow points to enhanced fluorescence signals. The abbreviated mouse
designations are as described in the legend to Figure 1. The labels are as follows: CP, choroid plexus; IZ, intermediate zone; NC, neocortex; OE,
olfactory epithelium; OL, olfactory lobe; VZ/SVZ, ventricular zone/subventricular zone.
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was detected in the heart and lung held in the thoracic
cavity (Figure 4A), but EGFP signals appeared when fro-
zen sections were examined (Figure 4B, (c)). The salivary
gland showed strong fluorescence signals (Figure 4A).
This structure in the rodent and in humans is composed
of three pairs of glandular organs, i.e., parotid gland,
sublingual gland and submandibular gland [31]. The
signal was found predominantly in the sublingual gland
(Figure 4B, (d)). The sublingual gland contains well-
developed striated duct system that produces mucous
secretion [31]. In whole-mount specimens of male uro-
genital organs, the prostate showed less pronounced
signals in contrast to the kidney and the testis, which
showed strong signals (Figure 4B, (e) (ii)). The testis is
composed of seminiferous tubules that primarily con-
tain germ cells and Sertoli cells, and interstitial tissues
that mainly contain Leydig cells responsible for produc-
tion and secretion of testosterone [32,33]. Strong EGFP
expression was found in the interstitial tissue but not in
seminiferous tubules (Figure 4B, (e) (iii) & (iv)). EGFP ex-
pression in the liver, kidney and intestine has previously
been addressed [20] and is not further studied here.
EGFP mRNA expression in tissues of the transgenic
mice was examined by northern blotting to detect the
1.0-kb transcript of the Tg (ASS-Ex3-EGFP) lines, andthe 4.1- and 3.1-kb transcripts of the Tg (ASS-Ex16-
EGFP) lines (Figure 4C, left panel). In both transgenic
lines, the highest EGFP expression levels were detected
in the liver and kidney. The relative EGFP RNA levels
in the tissues analyzed were similar between Tg (ASS-
Ex3-EGFP) and Tg (ASS-Ex16-EGFP) indicating that
tissue-specific expression is mainly controlled by pro-
moter activities. The ASS transgene in the transgenic
model is of human origin. We showed that expression
of the human ASS gene in the liver of the transgenic
mice followed the mouse Ass developmental pattern.
Conversely, the EGFP mRNA expression profile in the
small intestine resembles the human ASS in that sub-
stantial levels of EGFP mRNA could still be detected at
8 weeks of age in contrast to mouse Ass mRNA that
disappears at 3 weeks after birth [20]. Indeed, when the
endogenous Ass mRNA levels were studied in wild-type
mouse (Figure 4C, WT in left panel), the intestine showed
relatively low expression whereas the liver and kidney
showed the highest Ass mRNA levels, followed by that of
the testis. Besides the intestine, relative low Ass mRNA
level was found in the muscle when compared to that of
EGFP mRNA in the transgenic mice. Whether this was
due to the difference in ASS expression profiles between
human and mouse as occurred in the intestine requires





































































































































































Figure 4 Expression of the ASS-EGFP reporter gene in adult transgenic mice. (A) Gross anatomy displaying EGFP fluorescence. Male mice of
3.5 month-old Tg (ASS-Ex3-EGFP) 3G line were sacrificed to display the internal organs. Images after peritoneal wall incision (left panel) and after
gastrointestinal tract removal (middle panel) were acquired with a Canon PowerShot G11 digital camera built with blue filter. Fluorescence
images were taken with an exposure time of 2 seconds. Right panel, comparison of fluorescence signals among the mouse lines. The abbreviated
mouse designations are as described in the legend to Figure 1. non-Tg: a non-transgenic control. Images were taken with an exposure time of
4 seconds. (B) Study of EGFP fluorescence in (a) brain, (b) spleen and pancreas, (c) lung and heart, (d) salivary gland and (e) male urogenital
system of the 3G line. Panels (i) and (ii) are whole-mount specimens examined under white and fluorescent light of a dissecting microscope,
respectively. The rest of the panels were frozen sections examined by fluorescence microscopy. Top panel of (b) (iv) is a fluorescence image and
the bottom one is that stained with DAPI. Panel (iv) of (e) is a higher magnification view of the testis counterstained with DAPI to show location
of the interstitial tissue and seminiferous tubule. (C) Northern blot analysis. Left panel, detection of EGFP RNA expression in tissues of 3.5-month-
old mice using an EGFP probe. The lane at the far right was RNA from a non-transgenic liver. The bottom lane was an analysis of Ass mRNA from
a wild-type mouse using an ASS cDNA probe. Right panel, analysis of mouse Ass RNA and human ASS RNA in tissues of 27-day-old mice of the
Tg (ASS-Ex16-EGFP) lines using an ASS cDNA probe. Lines 16H, 16 F and 16E carry 2, 5 and 10 transgene copies, respectively.
Shiue et al. Journal of Biomedical Science  (2015) 22:10 Page 8 of 14the spleen was low in the transgenic lines in contrast to a
substantial high Ass mRNA level in wild-type mouse. Ass
mRNA was found at a low level in the rat spleen and
increased markedly by bacterial lipopolysaccharidetreatment [34]. Apparently, ASS expression level in the
spleen is influenced by environmental conditions. On the
other hand, to determine the relative ASS RNA levels of
human and mouse, northern blot was performed in lines
Shiue et al. Journal of Biomedical Science  (2015) 22:10 Page 9 of 1416H, 16 F and 16E of Tg (ASS-Ex16-EGFP), which carry 2,
5 and 10 transgene copies, respectively. The level of hu-
man ASS RNA was higher than that of mouse Ass RNA in
multiple tissues examined (Figure 4C, right panel). Not-
ably, the human ASS RNA in the liver was estimated to be
2-, 10- and 12-fold higher than that of the mouse RNA in
lines 16H, 16 F and 16E, respectively. Since ASS is a po-
tential limiting step in NO production [2], Tg (ASS-Ex16-
EGFP) is particularly suitable for studying the effects of
ASS overproduction on NO action during inflammation
or disease progression.
ASS-EGFP transgene expression in the brain of young mice
Localization of ASS in the brain has previously been
studied by immunocytochemical methods and was foundFigure 5 Spatial expression of ASS-EGFP in the brain of a 4 week-old
The insert of each micrograph indicates the location in brain where the im
cells in the glomerular layer in both major olfactory bulb (MOB) and access
septum region, significant EGFP expression is found in septal nuclei, i.e., LS
expressing EGFP whereas no significant EGFP expression was found in othe
the hypothalamus region. (D) Cells of choroid plexus in the lateral ventricle
third ventricle (D3V) exhibiting strong EGFP expression. (F) At the level of b
(4V) exhibited strong EGFP expression. Abbreviations: 4V, 4th ventricle; Acb
olfactory nucleus external; BS, brain stem; CA1, subregion of hippocampus;
putamen; CTX, cerebral cortex; D3V, dorsal 3rd ventricle; DCN, deep cerebe
external plexiform layer/AOB; Ep/OV, ependyma/olfactory ventricle; fi, fimbr
granule layer of olfactory bulb; Hb, habenular nucleus; HTM, hypothalamu
part; LSI, lateral septal nucleus, intermediate part; LV, lateral ventricle; MI,
medial septal nucleus; MVePC, medial vestibular nucleus, parvicellular par
TH, thalamus.to be constitutively expressed in neurons and astrocytes
[35,36]. During brain inflammation, ASS is also expressed
in microglial cells [37]. Nitric oxide (NO), an important
signaling molecule, is widely used in the nervous system
[38]. Abnormal NO signaling is known to contribute to a
variety of neurodegenerative pathologies [38]. Conceiv-
ably, ASS, acting as an integral part of the NO producing
pathway, would affect the neuromodulatory system in the
brain [2,38]. Moreover, in the brains of Alzheimer pa-
tients, ASS and inducible nitric oxide synthase are found
to co-express in neurons and glial cells [36]. In addition to
the function as a potential limiting step in NO production,
ASS may have a direct role in neuromodulation. This is
because the product of ASS, argininosuccinate, has
been implicated as a putative neuromodulator [2,35].Tg(ASS-Ex3-EGFP)3G mouse. Representative micrographs are shown.
age was taken. The scale represents 500 μm. (A) Granule neurons and
ory olfactory bulb (AOB) exhibiting strong EGFP expression. (B) In the
D, LSI and MS. (C) In the thalamus, neurons of habenular nuclei are
r nuclei of thalamus. Relatively weak EGFP expression was detected in
(LV) and the dorsal third ventricle (D3V) and (E) that in the dorsal
rain stem and cerebellum, cells of choroid plexus in the 4th ventricle
, nucleus accumbens; AOB, accessory olfactory bulb; AOE, anterior
CB, cerebellum; cc, corpus callosum; CP, choroid plexus; CPu, caudate
llar nuclei; DG, dentate gyrus; EPi, external plexiform layer; EPiA,
ia; Gl, glomerular layer; GlA, glomerular layer/AOB; GL, granule layer; Gr,
s; ICjM, islands of Calleja/major; LSD, lateral septal nucleus, dorsal
mitral cell layer; MOB, major olfactory bulb; ML, molecular layer; MS,
t; OCTX, orbital cortex; RSGc, retrosplenial granular cortex; S, septum;
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bral dysfunction. A recent report by Grady et al. [39] pro-
vides evidences that ASS depletion produces a cellular
metabolic state conducive to herpes simplex virus 1 infec-
tion. It is plausible that neurons in ASS-expressing brain
regions might be susceptible to viral infection due to
metabolic states that cause decreased ASS level. There-
fore, localization of ASS expression in the brain is of
great importance.
ASS-EGFP expression in the brain of 4 week-old Tg
(ASS-Ex3-EGFP) 3G mice was examined. Under a fluor-
escence microscope, serial frozen coronal sections from
the olfactory bulb to the cerebellum revealed specific
brain areas that exhibited EGFP signals (Figure 5). Sig-
nificant EGFP signals indicative of ASS expression is
present in the olfactory bulb (Figure 5A), septum area
(Figure 5B), habenular nucleus of thalamus (Figure 5C)
and the choroid plexus of all ventricles (Figure 5D to 5F).
Mouse olfactory bulb, located at the most anterior part
of the brain, is responsible for the sense of smell [40,41].
The bulb is divided into two distinct structures: the main
olfactory bulb (MOB) and the accessory olfactory bulb
(AOB) [40,41]. Both are multilayered structures, and in
our transgenic mice showed significant EGFP expres-
sion in the granule cell layer (Gr), the glomerular layer
(Gl) and ependyma cells lining the olfactory ventricle
(Ep/OV). In contrast, the orbital cortex (OCTX) showed
no detectable EGFP signals (Figure 5A). EGFP is ex-
pressed in cells of the olfactory bulb but not in other
constituent parts related to smell, i.e., olfactory tubercle
and piriform cortex, suggesting that the olfactory bulb
might bear localized functions, a proposition that re-
quires further investigation.
Septum, a structure of the limbic brain, has been impli-
cated in cognition and emotion. This subcortical structure
has rich connections with the hippocampus, amygdale
and the thalamus, the major sensory relay station to and
from the cerebral cortex [42,43]. Strong and clear EGFP
signals were present in septal nuclei including lateral sep-
tal nucleus dorsal part (LSD), lateral septal nucleus in-
termediate part (LSI) and medial septal nucleus (MS)
(Figure 5B). Expression of nitric oxide synthase in the
septum and that of NO in the septohippocampal choliner-
gic system have been implicated to control the generation
of theta (θ) wave, which is linked to mechanisms of learn-
ing and memory [44]. The septum also serves as a reward
center by inhibiting negative emotions and expressing the
pleasurable sensation via inhibitory signals sent to amyg-
dale [45]. Lower cell density in septal nuclei has been re-
ported in patients with mental disorders such as bipolar
disorder, major depressive disorder and schizophrenia
[46], further supporting the notion that septal nuclei are
important in emotional regulation. The intense EGFP
expression in the septum, a brain area endowed with somany important functions, makes the delineation of the
role of ASS in each nuclei with their respective con-
necting brain areas a challenge in future studies.
EGFP expression was also detected in the habenular
nuclei of the thalamus (Figure 5C). This medial-located
pair of nuclei and the pineal body constitutes the epi-
physis which, together with the suprachiasmatic nucleus
(SCN) of the hypothalamus, is responsible for the circa-
dian control of behavior such as locomotor rhythm [47].
More recently, habenula has been identified as the key
brain structure responsible for stress evasion and value-
based decision making [48]. Recent evidence also indi-
cated that altered basal ganglia activity leads to lateral
habenula hyperactivity, which in turn down-regulates
the serotonergic system, resulting in depressive symp-
toms in patients with Parkinson’s disease [49].
The choroid plexus (CP) located in the lateral ventricle
(Figure 5D) the third ventricle (Figure 5E) and the fourth
ventricle (Figure 5F) all exhibited strong EGFP signals.
The choroid plexus is a highly vascularized tissue located
in each ventricle of the brain known for generating the
cerebrospinal fluid (CSF) [50]. Recent progresses have
shown that CP and the instructive signals in the CSF may
provide means for regulating brain structure and function
in health and in diseases [51]. In particular, choroid plexus
may release into CSF morphogens EGF, FGF-2 and retin-
oic acid, which are keys to adult neurogenesis [51]. Chor-
oid plexus is also the source of phosphorylated Tau and
Aβ in CSF, the ratio of the two may serve as an important
index for detecting, diagnosing and treating Alzheimer
disease in the aging brain [51].
It would also be interesting to learn the similarities
and differences of ASS expression patterns between brains
of primates and rodents. The functional significance of the
differences, if any, can conceivably be explored by using
the mouse as an experimental model [52]. Nevertheless,
Ass brain profile using the BAC transgenic reporter is not
yet available in Gene Expression Nervous System Atlas
(GENSAT) [53] to allow comparison of ASS expression
patterns across species.
Down-regulated EGFP expression in hepatocellular
carcinoma (HCC) in the Tg (ASS- EGFP) transgenic mice
Loss of ASS function has been reported in cancer cells,
including HCC [54,55]. In this work, transgenic mice
harboring the EGFP reporter driven by ASS regulatory
elements were used to examine correlation between HCC
tumorigenesis and ASS expression. To generate HCC
mice, Tg (ASS-Ex3-EGFP) and Tg (ASS-Ex16-EGFP) mice
were crossed with transgenic mice harboring the HBx
gene of the hepatitis B virus [22] to produce Tg (ASS-
EGFP, HBx) double transgenic mice. The mice were kept
in specific pathogen-free conditions. At about 24 months
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Figure 6 Down-regulated ASS-EGFP expression in HBx-induced hepatocellular carcinoma in Tg (ASS-EGFP, HBx) double transgenic mice.
In all subfigures, mice are denoted by the ASS-EGFP designations as in Figure 1, followed by HBx to indicate double transgenics; the numerical
after HBx denotes the specific mouse analyzed. The 16C line used in 16C. HBx-1 (A) and 3 F line in 3 F. HBx-1 (B) carry 3 and 2 transgene copies,
respectively. (A) Localization of EGFP levels in tumor nodules observed under a fluorescence dissecting microscope. The age of the mice in
months (m) when sacrificed is shown in the bottom right corner of each image. Yellow and pink arrows indicate reduced and enhanced EGFP
fluorescence, respectively; the white arrow indicates apparently unaltered fluorescence levels compared with the surrounding tissue. HBx was
single transgenic mouse; WT, a non-transgenic control. (B) Correlation of tumor morphology and EGFP expression. Liver frozen sections were
taken from tumors of the transgenic lines. WT was a non-tumorous section from a normal mouse used as a control. Top panels, fluorescence
sections; bottom panels, DAPI-stained sections. Yellow arrows indicate sites of down-regulated EGFP expression. (C) Immunohistochemical analysis
of ASS and EGFP expression in tumors of the Tg (ASS-EGFP, HBx) double transgenic mice. Tumor tissues were reacted with an anti-ASS or anti-
EGFP antibody and incubated with the biotinylated secondary antibody coupled with streptavidin conjugated-HRP. HRP activities were visualized
by the application of chromogen DAB to produce brown coloration while the slides were counterstained with hematoxylin. (D) Histochemical
analysis of selected tumor morphology of the double transgenic mice. After HE staining, the tissue samples were observed under a light
microscope. Boxed field in the top panel is magnified and is shown in the bottom panel. Yellow arrows indicate central-sinusoidal trabecular
pattern; red arrows indicate peripheral-sinusoidal trabecular pattern.
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bodyweight of each double transgenic mouse were de-
termined as an indication of hepatomegaly. The liver-to-
bodyweight mean weight ratio of the double transgenic
mice was 0.070 ± 0.031, and was significantly higher than
that of non-transgenic mice of the same age and strain,
which was 0.040 ± 0.003 (p < 0.05, Student t test). The re-
sults clearly indicated hepatomegaly in the double trans-
genic mice, in which HCC nodules were, indeed, observed
in the liver (Figure 6).
At about 24 months of age, the mice were sacrificed
and the livers were removed for analysis. When exam-
ined under a fluorescence dissecting microscope, EGFP
fluorescence in the tumor sites was significantly lower in
intensity than that of the surrounding non-tumorous tis-
sues in both Tg (ASS-Ex3-EGFP)- and Tg (ASS-Ex16-
EGFP)-derived HBx double transgenic mice (Figure 6A,
yellow arrows). The results indicate down-regulated tran-
scriptional activities of the ASS regulatory elements in
driving the expression of the EGFP transgene, consistent
with down-regulated ASS expression in HCC in human
subjects [16]. It was noted that a minority of the tumors
showed enhanced (Figure 6A, pink arrows) or no change
(Figure 6A, white arrow) in EGFP fluorescence intensity,
suggesting possible microenvironmental influences on the
ASS promoter activities in the transgenic mice.
To examine the morphology of the HCC developed in
the double transgenic mice, frozen HCC sections were
examined (Figure 6B). The results again showed decreased
fluorescence intensity in most tumor nodules in both the
Tg (ASS-Ex3-EGFP)- and Tg (ASS-Ex16-EGFP)-derived
HBx double transgenic lines. On DAPI staining, nuclei in
the tumor tissues were smaller and denser, and were mor-
phologically distinctive to the surrounding structure of the
liver (Figure 6B). Immunohistochemical studies were also
performed to demonstrate that ASS and EGFP proteins
indeed decreased in the tumor nodules (Figure 6C). More-
over, when HE-stained paraffin-embedded tissue sections
were examined, typical HCC morphologies includingcytoplasmic lipid droplets, basophilic cells and trabecular
patterns were observed (Figure 6D). In the HCC, there
were relatively more cells with cytoplasmic lipid droplets
(Figure 6D, left panels), consistent with frequent asso-
ciation of fatty liver with HCC. The morphology of the
basophilic cells was similar to the DAPI-stained morph-
ology of frozen sections of the HCC nodules (Figure 6B)
in being numerous and dense and in having smaller nu-
clei (Figure 6D, middle panels). In well-differentiated
HCC, the regularly-seen trabecular pattern is HCC in-
tersperses with sinusoids. HCC trabecular patterns are
divided into two morphological types: central-sinusoidal
and peripheral-sinusoidal pattern [56]. In the central-
sinusoidal pattern of the double transgenic mice, sinusoids
were narrower and were branched, and formed multi-
layered HCC morphology (Figure 6D, yellow arrows). In
the peripheral-sinusoidal pattern, sinusoids were wider
and the HCC cells were enclosed by endothelium to
form multiple layers of trabeculae, which were separated
(Figure 6D, red arrows). Taken together, the HBx double
transgenic mice developed histologically-verified HCC
in which ASS expression was down-regulated, strongly
supporting close resemblance of the transgenic mouse
model with the clinical patterns of ASS expression in
cancers. Moreover, down-expression of ASS occurred
in HCC from both the Tg (ASS-Ex3-EGFP)- and Tg
(ASS-Ex16-EGFP)-derived HBx double transgenic lines,
suggesting that mechanism (s) affecting promoter ac-
tivity are involved.
The transgenic mouse model documented in this study
may also be exploited for prostate, pancreatic, renal can-
cers and melanoma that show down-regulated ASS ex-
pression [13–15], especially when EGFP was shown to
be expressed in these tissues in the Tg (ASS-EGFP) mice
(Figure 4). Conceivably, using our mouse model, epigen-
etic regulation of ASS transcription and drug or immuno-
logical evasion in treating cancers may be investigated and
the level of EGFP fluorescence can be used as a direct
monitor of the effects.
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We report in this work the development of two ASS-
EGFP transgenic mouse lines based on the use of modi-
fied BAC cassettes: the transcription reporter mice Tg
(ASS-Ex3-EGFP) and the transcription/post-transcription
couple reporter mice Tg (ASS-Ex16-EGFP). These two
transgenic lines permit temporal and spatial expression
profiling of ASS gene expression, thus, contributing in-
sights to regulated ASS expression. Particularly, by com-
paring the expression profiles between these two lines,
signals and the regulatory elements involved in novel
regulation of ASS precursor RNA stability may be de-
duced. Moreover, the ASS expression profile in the brain
should provide appropriate paths to pursuit functional
roles of ASS in the nervous system. In this respect, the
Tg (ASS-Ex16-EGFP) mouse line is highly suitable for
examination of the influence of human ASS expression
on mouse behavior upon inflammation or aging. Like-
wise, effects of ASS overexpression on the development
of HCC in double transgenic mice of Tg (ASS-Ex16-
EGFP, HBx) at resting state and upon exogenous insults,
such as virus infection or inflammation, can further be
analyzed using this transgenic mouse system.
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